Immunosuppression and outcomes of patients transplanted for hepatitis C.
Lake
John R
JR
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D016572:Cyclosporine / Q000627:therapeutic use; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology; D006526:Hepatitis C / Q000188:drug therapy* / Q000601:surgery*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000276:immunology; D008099:Liver / Q000737:chemistry / Q000473:pathology / Q000821:virology; D016031:Liver Transplantation / Q000276:immunology*; D016853:Muromonab-CD3 / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D012333:RNA, Messenger / Q000032:analysis; D012367:RNA, Viral / Q000032:analysis; D012008:Recurrence; D016559:Tacrolimus / Q000627:therapeutic use; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D012333:RNA, Messenger; D012367:RNA, Viral; D016572:Cyclosporine; D009173:Mycophenolic Acid; D016559:Tacrolimus